Avenue Therapeutics, Inc.
ATXI
$0.7727
-$0.0003-0.04%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.33% | 49.56% | 12.71% | -192.15% | -107.18% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.13% | -149.03% | 99.00% | 127.31% | -333.33% |
| Change in Net Operating Assets | -155.69% | -155.56% | -197.53% | -171.08% | 361.08% |
| Cash from Operations | 6.29% | 21.67% | -51.93% | -24.42% | -143.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 50.00% | -- | -- | -- |
| Cash from Investing | 100.00% | 50.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.44% | -4.10% | -36.27% | -35.37% | 203.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,466.67% | -- | -- | -- | 106.14% |
| Cash from Financing | -8.55% | -5.19% | -34.35% | -28.60% | 234.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,450.00% | 391.63% | -178.74% | -267.23% | 84.78% |
